DDInter1137 DDInter782
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Medrysone
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Hydrocortamate
Medroxyprogesterone acetate {u} (Compound) treats {v} (Disease) uterine cancer
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) SPAG4
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
Medroxyprogesterone acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Medroxyprogesterone acetate {u} (Compound) downregulates {v} (Gene) USP22
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Palpitations
Medroxyprogesterone acetate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Medroxyprogesterone acetate (Compound) resembles Medrysone (Compound)
Medroxyprogesterone acetate (Compound) resembles Hydrocortamate (Compound)
Medroxyprogesterone acetate (Compound) treats uterine cancer (Disease)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene)
Medroxyprogesterone acetate (Compound) upregulates SPAG4 (Gene)
Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease)
Medroxyprogesterone acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Medroxyprogesterone acetate (Compound) downregulates USP22 (Gene)
Medroxyprogesterone acetate (Compound) causes Palpitations (Side Effect)
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Delavirdine